Imunon, Inc.

IMNNCIK 0000749647

Analytics Research this company

Financial snapshot

Revenue

Net income

Operating margin

Free cash flow

Total debt

Cash

Research

Filings

Open the filing explorer →

Recent filings load as you scroll to this section.

Analytical signals

How signals work →

Calculations over this company’s filings, each compared with a stated threshold. They indicate where to read more closely; they are analytical evidence, not conclusions, and none implies wrongdoing.

Insider filing timing

P-08 · Calculated

Threshold met

FY 2026-06-30

Whether several insiders filed Form 4 in the 14 days before recent 8-K events.

3 8-K event(s) preceded by clustered Form 4 activity within 14 days

P-08 inputs
Input	Value
model score (0–100)	100.0
clusters.0.event_8k	2026-06-30
clusters.0.form4_count	6
clusters.0.form4_dates	["2026-06-23","2026-06-29"]
clusters.1.event_8k	2026-06-04
clusters.1.form4_count	6
clusters.1.form4_dates	["2026-05-27"]
clusters.2.event_8k	2026-01-07
clusters.2.form4_count	10
clusters.2.form4_dates	["2026-01-06"]
form4_total_1y	41
events_8k_1y	12
window_days	14
note	Timing pattern only — direction (buy/sell) requires parsing each Form 4 XML; treat as a read-the-filings triage flag, not an accusation.

Basis: Insider and event filingsMethodology

Strategic-review language

P-10 · AI-assisted, quote-verified

Threshold met

FY 2026-03-31

Activist 13D/13G filings, and language about strategic alternatives in MD&A and risk factors.

3 strategic-language signal(s) in the 10-K

P-10 inputs
Input	Value
model score (0–100)	54.0
sc13d_filings
ai_signals.0.kind	strategic_review
ai_signals.0.summary	Company may consider and evaluate strategic alternatives, including acquisitions.
ai_signals.0.quote	We may also consider and evaluate strategic alternatives, including investment in, or acquisition of, complementary businesses, technologies, or products.
ai_signals.0.quote_verified	true
ai_signals.1.kind	other
ai_signals.1.summary	Substantial doubt about going concern increases likelihood of seeking a buyer or merger partner.
ai_signals.1.quote	Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.
ai_signals.1.quote_verified	true
ai_signals.2.kind	segment_divestiture
ai_signals.2.summary	Company may be forced to relinquish assets or rights to technologies, drug candidates, or products to obtain funding.
ai_signals.2.quote	or obtain funds through other arrangements that may require us to relinquish some of our assets or rights to certain of our existing or future technologies, drug candidates, or products on terms not favorable to us.
ai_signals.2.quote_verified	true
quotes_discarded_unverified	0
ai_status	ok
method	Deterministic 13D count + LLM language read (quote-verified)

Basis: Filing text (AI-assisted, quote-verified)Methodology

ESG disclosure support

P-03 · AI-assisted, quote-verified

Elevated

FY 2026-03-31

How many environmental and social claims in the annual report are backed by a target, date or baseline.

6 of 10 ESG claims lack quantitative support (60% gap)

P-03 inputs
Input	Value
model score (0–100)	60.0
claims.0.claim	Ovarian cancer is a lethal gynecological malignancy with high five-year mortality.
claims.0.category	social
claims.0.quote	Ovarian cancer is the most lethal of gynecological malignancies among women with more than 60% of women dying within five years of diagnosis.
claims.0.quantified	true
claims.0.metric	five-year mortality rate
claims.0.quote_verified	true
claims.1.claim	The annual U.S. burden of ovarian cancer includes about 20,000 new cases and 13,000 deaths.
claims.1.category	social
claims.1.quote	There were approximately 20,000 new cases of ovarian cancer in the U.S. in 2021 with an estimated 13,000 deaths.
claims.1.quantified	true
claims.1.metric	new cases and deaths in 2021
claims.1.quote_verified	true
claims.2.claim	Five-year survival rates for advanced ovarian cancer are low, indicating unmet need.
claims.2.category	social
claims.2.quote	With the five-year survival rates for Stages III and IV at 41% and 20%, respectively, there remains a need for a therapy that not only reduces the recurrence rate but also meaningfully improves overall survival.
claims.2.quantified	true
claims.2.metric	five-year survival rates by stage
claims.2.quote_verified	true
claims.3.claim	Many newly discovered pathogenic viruses lack prophylactic vaccines, highlighting an urgent public health need.
claims.3.category	social
claims.3.quote	Since 1980, more than 80 pathogenic viruses have been discovered, yet fewer than 4% have a commercially available prophylactic vaccine.
claims.3.quantified	true
claims.3.metric	virus discovery and vaccine availability percentages
claims.3.quote_verified	true
claims.4.claim	Vaccines addressing multiple viral strains are a public health need.
claims.4.category	social
claims.4.quote	There is a clear public health need for vaccines today that address more than one strain of viruses, like COVID-19, which have fast evolving variant capability to offer the widest possible protection.
claims.4.quantified	false
claims.4.metric	null
claims.4.quote_verified	true
claims.5.claim	The polymer delivery system is biocompatible and reduces the risk of adverse immune response.
claims.5.category	social
claims.5.quote	The biocompatibility of these polymers reduces the risk of adverse immune response, thus allowing for repeated administration.
claims.5.quantified	false
claims.5.metric	null
claims.5.quote_verified	true
claims.6.claim	IMNN-001 was well tolerated with no dose-limiting toxicities in the OVATION 1 Study.
claims.6.category	social
claims.6.quote	IMNN-001 was well tolerated, and no dose-limiting toxicities were detected in the OVATION 1 Study.
claims.6.quantified	false
claims.6.metric	null
claims.6.quote_verified	true
claims.7.claim	IMNN-001 plus chemotherapy was generally well tolerated with no serious immune-related adverse events.
claims.7.category	social
claims.7.quote	Treatment was also generally well tolerated, with no reports of cytokine release syndrome or any other serious immune-related adverse events.
claims.7.quantified	false
claims.7.metric	null
claims.7.quote_verified	true
claims.8.claim	IMNN-001 continued to show a favorable safety profile with no serious immune-related adverse events.
claims.8.category	social
claims.8.quote	IMNN-001 was generally safe and well tolerated, with no reports of cytokine release syndrome, systemic toxicity or serious immune-related adverse events.
claims.8.quantified	false
claims.8.metric	null
claims.8.quote_verified	true
claims.9.claim	IMNN-101 was safe and well tolerated in a Phase 1 trial.
claims.9.category	social
claims.9.quote	Results demonstrated that IMNN-101 is safe and well-tolerated with no serious adverse effects.
claims.9.quantified	false
claims.9.metric	null
claims.9.quote_verified	true

Basis: Filing text (AI-assisted, quote-verified)Methodology

Interest coverage

P-13 · Calculated

Elevated

FY 2023-12-31

Whether operating earnings cover interest expense, and for how many consecutive years they did not.

[FY2023 data, stale — no more recent EBIT figure in XBRL] EBIT is negative: operating earnings do not cover interest expense

Trend: flat

P-13 inputs
Input	Value
model score (0–100)	100.0
icr_by_year.2025-12-31	null
icr_by_year.2024-12-31	null
icr_by_year.2023-12-31	-106.71
icr_by_year.2022-12-31	-4.956
consecutive_years_below_1	2
altman_z_double_prime	-59.289
definitions.zombie	ICR<1 for 3+ consecutive FYs (BIS 2018)
definitions.z_distress	<1.1 distress, 1.1-2.6 gray, >2.6 safe
inputs.ebit_t	-21030430
inputs.interest_expense_t	197080
stale	true
latest_filing_period	2025-12-31

Trend

10-K· 2025-02-27 Methodology

Carbon-exposed assets

P-11 · AI-assisted, quote-verified

Below threshold

FY 2026-03-31

No carbon-exposed asset language detected

How asset-heavy the balance sheet is, and whether the filing names carbon-exposed asset classes.

P-11 inputs
Input	Value
model score (0–100)	0.0
exposures
ppe_share_of_assets	null
quotes_discarded_unverified	0

Basis: Filing text (AI-assisted, quote-verified)Methodology

Language change

P-09 · Calculated

Below threshold

FY 2026-03-31

Filing language stable vs prior 10-K

How the density of uncertainty, negative and litigious wording changed between the latest and prior annual report.

P-09 inputs
Input	Value
model score (0–100)	4.4
current.filed	2026-03-31
current.tokens	60741
current.uncertainty_per_1k	14.47
current.negative_per_1k	6.29
current.litigious_per_1k	3.51
prior.filed	2025-02-27
prior.tokens	59622
prior.uncertainty_per_1k	13.95
prior.negative_per_1k	6.98
prior.litigious_per_1k	3.46
ratios.uncertainty	1.037
ratios.negative	0.901
method	Loughran-McDonald dictionary densities (lite subset unless full CSV present)

Basis: Filing textMethodology

Subsidiary jurisdictions

P-02 · Calculated

Below threshold

FY 2026-03-31

No watchlist-jurisdiction subsidiaries in EX-21

Where the company's significant subsidiaries are domiciled, compared with a configurable list of jurisdictions.

P-02 inputs
Input	Value
model score (0–100)	0.0
exhibit	ex21-1.htm
filing_date	2026-03-31
watchlist	China, Russia, Belarus, Iran, North Korea
all_jurisdiction_mentions.Delaware	1
note	Mention-count proxy from EX-21; ownership %, revenue share and supply relationships require the LLM enrichment phase.

Basis: Exhibit 21Methodology

No stored result for Earnings quality, Effective tax rate, Pension funding, Restatement indicators. Some signals are computed on request, and others need inputs this company’s filings do not tag; a missing result is not a finding either way.

Methodology and sources

Financial figures come from SEC XBRL company facts (annual reports). Choose any evidence marker to see the filing behind a value.
Filing text comes from SEC EDGAR. Browse this company on EDGAR ↗
Signals are calculated by Stratum from those filings. Some use AI to read filing text, and every AI claim must quote the document verbatim or it is discarded. Full methodology

More tools: chat with the 10-K · generate an investigation memo